Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Get Free Report) shot up 9.8% during mid-day trading on Wednesday . Compass Point set a $25.00 target price on Compass Pathways in a report on Tuesday, July 7th. TD Cowen reissued a “buy” rating on shares of Compass Pathways in a research report on Monday, June 1st. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Compass Pathways Company Profile(Get Free Report)Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders.